To identify metabolic constraints within the cancer and T cell compartments in response to immune checkpoint blockade therapy, we administered anti-PD1 (αPD1) to CD4-Cre:RiboTag tumor-bearing mice and conducted DualRP analysis (Fig. 4a). Here, CD4 is linked to neoplasm.